|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Cleaning-in-place (CiP) technology has been employed in the food, pharmaceutical and medical, process and allied industries for many years. Systems have become increasingly automated, giving CiP systems a level of repeatability which guarantees that a CiP clean is being carried out correctly. After proving and commissioning that CiP cycles are operating effectively, the level of repeatability in some cases is relied upon to give implied 'proof' of the quality of the CiP cleans.
To enable this repeatability to be relied upon, the control system of the CiP technology should be validated. A validated system is basically a certified system which ensures that all aspects of the system have been subjected to full successful testing, with each separate test certified once it has been completed. Once validation is concluded it provides the assurance that the CiP will operate as expected, at all times, or in the case of equipment failure will inhibit cleans being completed when they are out of specification.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
2012 BIO International Convention
18-21 June 2012, Boston, Massachusetts
Connect, partner and innovate at the 2012 BIO International Convention, June 18-21, Boston, Mass. Network with 15,000+ global biotech leaders in the BIO Business Forum, Exhibition and Programme.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
